Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$37.02 USD
-0.75 (-1.99%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $36.96 -0.06 (-0.16%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Celldex Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -141.43 | -112.33 | -70.51 | -59.78 | -50.88 |
Depreciation/Amortization & Depletion | -3.21 | 3.74 | -0.14 | 3.20 | 3.72 |
Net Change from Assets/Liabilities | 13.46 | -3.90 | -1.05 | -0.30 | -4.32 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 23.89 | 8.75 | 10.80 | 16.48 | 5.07 |
Net Cash From Operating Activities | -107.29 | -103.73 | -60.91 | -40.40 | -46.42 |
Property & Equipment | -1.82 | -1.76 | -1.22 | -1.50 | -0.71 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -103.96 | 91.70 | -214.93 | -96.72 | 17.79 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -105.78 | 89.94 | -216.16 | -98.22 | 17.08 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 218.46 | 4.08 | 272.37 | 171.23 | 16.26 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 218.46 | 4.08 | 272.37 | 171.23 | 16.26 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 5.39 | -9.71 | -4.69 | 32.60 | -13.08 |
Cash at Beginning of Period | 29.43 | 39.14 | 43.84 | 11.23 | 24.31 |
Cash at End of Period | 34.81 | 29.43 | 39.14 | 43.84 | 11.23 |
Diluted Net EPS | -2.92 | -2.40 | -1.64 | -2.02 | -3.51 |
Fiscal Year End for Celldex Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -141.43 | -98.12 | -59.86 | -29.36 |
Depreciation/Amortization & Depletion | NA | -3.21 | -1.79 | -0.93 | -0.53 |
Net Change from Assets/Liabilities | NA | 13.46 | 8.48 | -4.53 | -3.02 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 23.89 | 16.68 | 9.56 | 4.34 |
Net Cash From Operating Activities | NA | -107.29 | -74.76 | -55.77 | -28.57 |
Property & Equipment | NA | -1.82 | -1.15 | -1.00 | -0.59 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -103.96 | 66.53 | 54.73 | 53.15 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -105.78 | 65.38 | 53.73 | 52.57 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 218.46 | 1.08 | 0.83 | 0.69 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 218.46 | 1.08 | 0.83 | 0.69 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 5.39 | -8.30 | -1.21 | 24.69 |
Cash at Beginning of Period | NA | 29.43 | 29.43 | 29.43 | 29.43 |
Cash at End of Period | NA | 34.81 | 21.13 | 28.22 | 54.12 |
Diluted Net EPS | NA | -0.84 | -0.81 | -0.65 | -0.62 |